Onconova Therapeutics (United States)

Recent papers from Onconova Therapeutics (United States)

1. ZAP327 signaling domain–driven chimeric antigen receptor generates robust and long-term antitumor immunity in mouse modelsScience Translational Medicine · 2025
2. Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinomaBritish Journal of Dermatology · 2025
3. Has the UK lost its position as a destination for world-leading clinical research? A comparative analysis of haematological cancer clinical trials performance before BrexitBMJ Open · 2024
4. Abstract PO5-24-01: Narazaciclib’s differential targets and kinase inhibitory activity contribute to the enhanced inhibition of tumor growth in preclinical modelsCancer Research · 2024
5. Abstract 2033: Rigosertib promotes anti-tumor activity of cancer cells via CETSA revealed novel targets and activates NLRP3-dependent inflammatory responsesCancer Research · 2024
6. Serum microRNA profile of rhesus macaques following ionizing radiation exposure and treatment with a medical countermeasure, Ex-RadScientific Reports · 2024
7. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics2023
8. JP ‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseasesPharmacology Research & Perspectives · 2023
9. Analysis of the Proteomic Profile in Serum of Irradiated Nonhuman Primates Treated with Ex-Rad, a Radiation Medical CountermeasureJournal of Proteome Research · 2023
10. Age-associated changes in microglia activation and Sirtuin-1- chromatin binding patternsAging · 2022
11. Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasureScientific Reports · 2021
12. Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with AzacitidineBlood · 2018
13. Proceedings of the fifth international RASopathies symposium: When development and cancer intersectAmerican Journal of Medical Genetics Part A · 2018
14. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive careBlood Cancer Journal · 2017
15. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents FailThe Oncologist · 2017
16. Analysis of professional competencies for the clinical research data management profession: implications for training and professional certificationJournal of the American Medical Informatics Association · 2017
17. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell linesOncotarget · 2016
18. Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional TherapiesBlood · 2014
19. Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic AgentsBlood · 2014
20. Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1st-Line TherapyBlood · 2014